Dorsey Wright & Associates’s CorMedix CRMD Stock Holding History

Dorsey Wright & Associates’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,668	Closed	-$18.5K	–	290
2023 Q2	$18.5K	Buy	+4,668	New	+$23.1K	0.01%	274

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Dorsey Wright & Associates's CRMD Position: Q3 2023 in Review

Dorsey Wright & Associates sold out of CorMedix (CRMD) in Q3 2023, closing a stake of 4,668 shares — an estimated $18.5K sold.

Dorsey Wright & Associates first reported a position in CRMD in Q2 2023 and held it in 1 quarter. The position peaked at $18.5K in Q2 2023. 92 funds tracked by Wall St. Rank hold CRMD as of Q3 2023.

Dorsey Wright & Associates reported no remaining CorMedix position as of Q3 2023 after selling out during the quarter.
Dorsey Wright & Associates sold 4,668 CorMedix shares in Q3 2023, an estimated $18.5K.
Dorsey Wright & Associates first reported a position in CorMedix in Q2 2023 and held it in 1 quarter.
Dorsey Wright & Associates's CorMedix position peaked at $18.5K in Q2 2023.
92 funds tracked by Wall St. Rank held CorMedix as of Q3 2023.

Based on Dorsey Wright & Associates's 13F filing for Q3 2023, filed 7 Nov 2023.